Prosecution Insights
Last updated: April 19, 2026

Examiner: GU, QINHUA

Tech Center 1600 • Art Units: 1633

This examiner grants 77% of resolved cases

Performance Statistics

76.6%
Allow Rate
+16.6% vs TC avg
85
Total Applications
+27.7%
Interview Lift
1455
Avg Prosecution Days
Based on 64 resolved cases, 2023–2026

Rejection Statute Breakdown

2.1%
§101 Eligibility
17.2%
§102 Novelty
43.5%
§103 Obviousness
27.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18285000 MODIFIED VIRUSES AND VIRAL PARTICLES, METHODS OF MAKING, AND USES THEREOF Non-Final OA The Regents of the University of California
18551562 RECOMBINANT VIRAL EXPRESSION VECTORS AND METHODS OF USE Non-Final OA North Carolina State University
17685457 ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF Final Rejection University of Massachusetts
18010964 GENETICALLY MODIFIED NON-HUMAN ANIMAL EXPRESSING A B2M/FCRN FUSION PROTEIN Non-Final OA Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
18273441 MATURATION AGENT Non-Final OA Orizuru Therapeutics, Inc.
18028464 USE OF COMPOUND FOR IMPROVING TRANSPLANTATION EFFICIENCY OF HUMAN HEMATOPOIETIC STEM CELLS Non-Final OA EDIGENE (GUANGZHOU) INC.
17670789 Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties Final Rejection Alliance of Cardiovascular Researchers

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month